Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Ebrahimi, Marzieh  [Clear All Filters]
2013
Roudi R, Madjd Z, Ebrahimi M, Samani FSahraneshi, Samadikuchaksaraei A. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cell Mol Biol Lett. 2013.
Ebrahimi M, Hassan ZMohammad, Mostafaie A, Mehrjardi NZare, Ghazanfari T. Purif ied Protein Fraction of Garlic Extract Modulates Cellular Immune Response against Breast Transplanted Tumors in BALB/c Mice Model. Cell J. 2013;15(1):65-75.
2015
Ganji F, Abroun S, Baharvand H, Aghdami N, Ebrahimi M. Differentiation potential of o bombay human-induced pluripotent stem cells and human embryonic stem cells into fetal erythroid-like cells. Cell J. 2015;16(4):426-39.
Fomeshi MRajabi, Ebrahimi M, Mowla SJavad, Khosravani P, Firouzi J, Khayatzadeh H. Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells. Cell Mol Biol Lett. 2015;20(3):448-465.
Abdollahi P, Ebrahimi M, Motamed N, Samani FS. Silibinin affects tumor cell growth because of reduction of stemness properties and induction of apoptosis in 2D and 3D models of MDA-MB-468. Anticancer Drugs. 2015.
2016
Fomeshi MRajabi, Ebrahimi M, Mowla SJavad, Firouzi J, Khosravani P. CD133 Is Not Suitable Marker for Isolating Melanoma Stem Cells from D10 Cell Line. Cell J. 2016;18(1):21-7.
Dashti A, Ebrahimi M, Hadjati J, Memarnejadian A, Moazzeni SMohammad. Dendritic cell based immunotherapy using tumor stem cells mediate potent antitumor immune responses. Cancer Lett. 2016.
2018
Abbaspanah B, Momeni M, Ebrahimi M, Mousavi SHadi. Advances in perinatal stem cells research: a precious cell source for clinical applications. Regen Med. 2018.
2019
Javadi A, Keighobadi F, Nekoukar V, Ebrahimi M. Finite-Set Model Predictive Control of Melanoma Cancer Treatment Using Signaling Pathway Inhibitor of Cancer Stem Cell. IEEE/ACM Trans Comput Biol Bioinform. 2019.
Sharifzad F, Ghavami S, Mardpour S, Mollapour M, Azizi Z, Taghikhani A, Łos MJ, Verdi J, Fakharian E, Ebrahimi M, et al. Glioblastoma cancer stem cell biology: Potential theranostic targets. Drug Resist Updat. 2019;42:35-45.
Shokraii F, Moharrami M, Motamed N, Shahhoseini M, Totonchi M, Ezzatizadeh V, Firouzi J, Khosravani P, Ebrahimi M. Histone Modification Marks Strongly Regulate CDH1 Promoter in Prostospheres as A Model of Prostate Cancer Stem Like Cells. Cell J. 2019;21(2):124-134.
Bakhshi M, Asadi J, Ebrahimi M, Moradi A-V, Hajimoradi M. Increased expression of miR-146a, miR-10b, and miR-21 in cancer stem-like gastro-spheres. J Cell Biochem. 2019.
Rahimi M, Sharifi-Zarchi A, Firouzi J, Azizmi M, Zarghami N, Alizadeh E, Ebrahimi M. An integrated analysis to predict micro-RNAs targeting both stemness and metastasis in breast cancer stem cells. J Cell Mol Med. 2019.
2020
Rahimi M, Sharifi-Zarchi A, Zarghami N, Geranpayeh L, Ebrahimi M, Alizadeh E. Down-Regulation of miR-200c and Up-Regulation of miR-30c Target both Stemness and Metastasis Genes in Breast Cancer. Cell J. 2020;21(4):467-478.
Azimi M, Totonchi M, Rahimi M, Firouzi J, Sahranavard P, Razavi AEmami, Memari F, Kamali F, Ebrahimi M. An Integrated Analysis to Predict micro-RNAs Targeting both Stemness and Metastasis in Human Gastric Cancer. J Gastroenterol Hepatol. 2020.
Taghikhani A, Sharifzad F, Mardpour S, Hassan ZMohammad, Ebrahimi M. Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response. Cancer Lett. 2020.
2021
Norouzi M, Firouzi J, Sodeifi N, Ebrahimi M, Miller DW. Salinomycin-loaded Injectable Thermosensitive Hydrogels for Glioblastoma Therapy. Int J Pharm. 2021:120316.
2022
Khani M, Burke B, Ebrahimi M, Irani S, Sotoodehnejad F. Comparison Study on the Effect of Mesenchymal Stem Cells-Conditioned Medium Derived from Adipose and Wharton's Jelly on Versican Gene Expression in Hypoxia. Iran Biomed J. 2022.
Moradi S, Kamal A, Es HAboulkheyr, Farhadi F, Ebrahimi M, Chitsaz H, Sharifi-Zarchi A, Baharvand H. Pan-cancer analysis of microRNA expression profiles highlights microRNAs enriched in normal body cells as effective suppressors of multiple tumor types: A study based on TCGA database. PLoS One. 2022;17(4):e0267291.
Hajimoradi M, Rezalotfi A, Esmaeilnejad-Ahranjani P, Hassan ZMohammad, Ebrahimi M. STAT3 inactivation suppresses stemness properties in gastric cancer stem cells and promotes Th17 in Treg/Th17 balance. Int Immunopharmacol. 2022;111:109048.
2023
Lamouty MAzimi, Asl NShayan, Safari A, Ebrahimi M, Daemi H. Fabrication of Cell-Laden AME-Loaded Collagen-Based Hydrogel Promotes Fibroblast Proliferation and Wound Healing . Cell J. 2023;25(4):255-263.
Firouzi J, Hajifathali A, Azimi M, Parvini N, Ghaemi F, Asl NShayan, Asl AAbbas Heda, Safa M, Ebrahimi M. Hsp70, in Combination with IL-15 and PD-1 Blocker, Interferes with The Induction of Cytotoxic NK Cells in Relapsed Acute Myeloid Leukemia Patients. Cell J. 2023;25(2):92-101.
Safarpour A, Ebrahimi M, Fazeli SAbolhassan, Amoozegar MAli. A phenol amine molecule from Salinivenus iranica acts as the inhibitor of cancer stem cells in breast cancer cell lines. Sci Rep. 2023;13(1):12669.
Izadpanah A, Mohammadkhani N, Masoudnia M, Ghasemzad M, Saeedian A, Mehdizadeh H, Poorebrahim M, Ebrahimi M. Update on immune-based therapy strategies targeting cancer stem cells. Cancer Med. 2023.
2024
Parvini N, Akbari MEsmaeil, Hamidieh AAli, Fathi F, Amini AAli, Ebrahimi M, Vahabzadeh Z. CTLA-4 Blockade of Natural Killer Cells Increases Cytotoxicity against Acute Lymphoid Leukaemia Cells Neda. Cell J. 2024;26(2):150-157.

Pages